Secondary analysis of a phase IIIb open-label trial in 676 patients with TRD (esketamine nasal spray vs quetiapine XR): 89.6% of esketamine Week 4 responders reached remission by Week 32, and symptom resolution across MADRS items was greater and earlier with esketamine.
Secondary analysisn = 676
Young et al. Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD